Topical fibronectin in the treatment of persistent corneal epithelial defects and trophic ulcers.
Six patients with persistent corneal epithelial defects that failed to improve with standard therapy were treated with topical fibronectin in a phase I uncontrolled trial. Fibronectin was purified from autologous plasma by affinity chromatography and administered topically, 0.5 mg/ml five times a day, for three weeks. Complete reepithelialization was achieved in five patients: three healed three to 17 days after initiation of treatment while two healed one to two weeks after discontinuation of topical fibronectin. No side effects were observed. Over a follow-up period of three to 18 months, two recurrences were noted.
Phan
T M
TM
Hilles Immunology Laboratory, Massachusetts Eye and Ear Infirmary, Boston.
Foster
C S
CS
Boruchoff
S A
SA
Zagachin
L M
LM
Colvin
R B
RB
D000287:Administration, Topical; D000368:Aged; D003315:Cornea / Q000473:pathology; D003316:Corneal Diseases / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D003320:Corneal Ulcer / Q000188:drug therapy / Q000473:pathology; D004341:Drug Evaluation; D004848:Epithelium / Q000473:pathology; D005260:Female; D005353:Fibronectins / Q000008:administration & dosage / Q000302:isolation & purification / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D014792:Visual Acuity; D014945:Wound Healing
D005353:Fibronectins